Results 181 to 190 of about 128,382 (221)

Toxicities of Fruquintinib in Gastrointestinal Malignancies: A Systematic Review and Meta-Analysis. [PDF]

Oncol Res
Jones DT, Sangha T, Manjikian A, Ghobrial M, Shawesh Q, Tiwana E, Hearn E, Latif A, Tupas E, Hanspal A, Nanda RK, Srinivasmurthy R, Ta J, Pandit M, Larson CAJ, Thein KZ.   +15 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Office Blood Pressure and Arteriolosclerosis in Biopsy-Proven Glomerulonephritis: Association With Renal Function Decline and Clinical Outcomes. [PDF]

J Clin Hypertens (Greenwich)
Gigante A, Trombacco A, Galanti G, Pellicano C, Sorato G, Cascone R, Rosato E, Giannakakis K, Cianci R.   +8 more
europepmc   +1 more source

Omnipod 5 Delivers Superior Economic Value Compared to Multiple Daily Injections: A Cost‐Effectiveness Analysis in Adults With T1D From a Payer Perspective in Sweden

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aim Analyse the cost‐effectiveness of the Omnipod 5 automated insulin delivery system versus multiple daily injections (MDI) with continuous glucose monitoring for type 1 diabetes among adults in Sweden. Methods Cost‐effectiveness was analysed with the IQVIA Core Diabetes Model (version 10.0) taking the perspective of the payer in Sweden ...
Johan Jendle, Colin Hopley, Anuj Narang, Raffaele Scarica, Helena Hellerstedt, Melanie Littlewood   +5 more
wiley   +1 more source

Clinical Predictors of Non-Diabetic Glomerular Disease in Type 2 Diabetic Patients With Nephrotic-Range Proteinuria. [PDF]

Nephrology (Carlton)
Tirasattayapitak S, Thammavaranucupt K, Limbutara K, Suphatheerawatr N, Pongsittisak W, Chavanisakun C, Benjakul N, Jaturapisanukul S.   +7 more
europepmc   +1 more source

Effectiveness of Adding GLP‐1 Receptor Agonists to SGLT2 Inhibitor Therapy in Chronic Kidney Disease: A Population Based Study

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Individually, sodium–glucose co‐transporter‐2 inhibitors (SGLT2i) and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) have been shown to reduce major kidney and cardiovascular events in patients with chronic kidney disease (CKD). However, evidence supporting combined GLP‐1RA and SGLT2i therapy in this population remains limited.
Hussain Salim, Shaheer Qureshi, Gaurav S. Gulsin, Habib R. Khan, Saad Ahmed Waqas, Gerry P. McCann, Amit Garg, Mohammed Shurrab, Kamlesh Khunti, Muhammad Rashid   +9 more
wiley   +1 more source

Renal Amyloidosis in Pediatric Autoinflammatory Syndromes: Subclinical Onset, Early Biomarkers, and Clues for Timely Characterization and Interventions. [PDF]

J Clin Med
Arsiwala N, Rigante D.
europepmc   +1 more source

Light Chain Monoclonal Gammopathy of Undetermined Significance: Diagnosis, Biology, and Clinical Management

European Journal of Haematology, EarlyView.
ABSTRACT Light chain monoclonal gammopathy of undetermined significance (LC‐MGUS) is defined by an abnormal serum free light chain ratio and elevated involved light chain in the absence of a detectable immunoglobulin heavy chain on immunofixation and of end‐organ damage attributable to a plasma cell disorder.
Sigurður Yngvi Kristinsson, Thórir Einarsson Long, Sigrún Thorsteinsdóttir   +2 more
wiley   +1 more source

The Three Faces of IgA Nephropathy: Clinicopathological Heterogeneity and Urinary Albumin-to-Protein Ratio in a Case Series. [PDF]

J Clin Med
Masajtis-Zagajewska A, Kieszek B, Nowicki M.   +2 more
europepmc   +1 more source

Expert Consensus on the Diagnosis and Monitoring of Paroxysmal Nocturnal Hemoglobinuria (PNH): An Algorithmic Approach in an Era of New Treatments

European Journal of Haematology, EarlyView.
ABSTRACT Paroxysmal nocturnal hemoglobinuria (PNH) is a rare hematologic disorder caused by a defect of glycosylphosphatidyl‐anchored proteins, leading to an uncontrolled complement‐mediated hemolysis. The advent of complement inhibitors in clinical practice radically changed patients' outcomes and survival.
Bruno Fattizzo, Monia Marchetti, Elisa Cannizzo, Arianna Gatti, Massimo Geuna, Anna Paola Iori, Maddalena Raia, Simona Sica, Francesco Buccisano   +8 more
wiley   +1 more source